Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Broker tips: Mothercare, Dr Martens

(Sharecast News) - Mothercare's forecast-beating annual results demonstrate "resilience and adaptability" according to Shore Capital, but that wasn't enough to change the broker's 'hold' rating. The broker said the current financial year is expected to be "another year of transition for the company" as it refinances to improve financial flexibility, improve profitability and appoint a new CEO (the search for a new boss has been reset, with interim management taking the helm for now).

The retailer reported on Friday that adjusted EBITDA fell 44% to £6.7m in the year to 25 March, just ahead of the market's £6.6m estimate.

Worldwide retail sales by franchise partners fell 16% to £323m, but for continuing markets (which excludes the Russian operations which were suspended last year) revenues actually rose by 9%.

"Perhaps the most significant positive was the considerable reduction in the pension scheme deficit, which stood at £35million, down from £78 million in March 2022 and a substantial £124.6 million in March 2020," said Shore Capital analysts.

"As the company navigates a leadership transition, it has also initiated refinancing discussions to better cope with rising interest rates. Looking ahead, Mothercare aims to complete the refinancing process soon and projects its franchise operations to exceed £10 million in operating profit.

"Therefore, we maintain our 'hold' rating for FY24F as the company seeks to diversify its brand further and penetrate new markets."

Equity research firm Edison reckons that Dr Martens' recent share-price underperformance could reverse if the iconic footwear retailer has a successful turnaround of operational issues in North America.

Following a recent "teach-in" day with the company last week, Edison hailed Dr Martens' ongoing product innovation, as well as its brand awareness and relevance among younger demographics through its collaborations with influencers and marketing campaigns on social media.

"DOCS' consumer base is very diverse as well as loyal, with the brand consistently above peers for sentiment scores among UK consumers, which continues to be a driver for the group's global growth prospects," said Russell Pointon, director of the consumer division at Edison.

The company also presented its sustainability strategy as it looks to target natural materials from regenerative agriculture by 2040 and removing fossil-fuel chemicals by 2035.

The shares are currently trading around the 140-150p level, not far off the record low of 113p reached in the summer after full-year results revealed that its North American performance was holding back group sales growth.

The company admitted at the time that it had made "operational mistakes" in the US, such as the move of a distribution centre and the execution of marketing campaigns and online trading. Management called the strategic review and turnaround of the regional business its "number one operational priority".

"DOCS currently trades on discounts of 48% and 32% for EV/EBITDA and P/E, respectively, in FY24 to global luxury, global footwear and sportswear brands. A weak share price performance since IPO in early 2021 due to a combination of operational issues and wider market effects means its valuation, naturally, looks low relative to its historical trading multiples," Pointon said.

He said that this valuation discount to the wider sector could "narrow" based on the performance in North America.

Share this article

Related Sharecast Articles

Broker tips: Volution, Videndum
(Sharecast News) - Jefferies reiterated its 'buy' rating and 510.0p target price on Volution on Wednesday as it said the company's ability to drive margins higher, through both revenue mix and efficiency, is more than offsetting the challenging market backdrop to deliver ongoing earning upgrades.
Broker tips: Marlowe, Fevertree
(Sharecast News) - Analysts at Berenberg slightly lowered their target price on software and services firm Marlowe from 720.0p to 710.0p on Tuesday but said the group's divestment of certain Governance, Risk and Compliance software and service assets had left it with a "much cleaner and simpler-to-understand equity story".
Broker tips: JD Sports, NatWest
(Sharecast News) - Barclays downgraded JD Sports on Monday to 'equalweight' from 'overweight' and cut its price target for the stock to 140.0p from 165.0p after the retailer announced the acquisition of US rival Hibbett last week for $1.1bn.
Broker tips: NatWest, Pensionbee, Greggs
(Sharecast News) - Shore Capital reiterated its 'buy' rating on bank NatWest after a forecast-beating first quarter but said it sees the least amount of upside potential in the stock compared with the wider banking sector.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.